Together, rare cancers make up more than 20% of all cancer cases. We’ve contributed to several advances for people with rare cancers. We ran some of the first trials for people with uveal melanoma and neuroendocrine tumours, and showed that the drug Glivec was effective for some advanced gastro-intestinal stromal tumours (GIST). And we set up and continue to support the International Rare Cancers Initiative, which is developing clinical trials worldwide to find new treatments for rare cancers.
From studying the biology of rare cancer cells in the lab to leading clinical trials testing cutting-edge treatments, our researchers are working hard to ensure more people survive rare cancers.
Thanks to research, we've helped change the outlook for people with rare cancers.
Meet people like Oliver who have experienced first-hand how our research is making a difference. The life-saving research we do wouldn’t be possible without your support.
Over the last 40 years, cancer survival in the UK has doubled. In the 1970s just 1 in 4 people survived their disease for 10 years or more. Today 2 in 4 survive.
We want to accelerate progress and see 3 in 4 patients surviving the disease by 2034.
Browse the latest news, analysis and opinion from Cancer Research UK.
Want to find more information about our research or rare cancers?
